Prior to founding Intensity Therapeutics, from January 2008 until August 2012 Lew Bender was the CEO of Interleukin Genetics, a personalized medicine company. At Interleukin Mr. Bender successfully restructured the Company, increased sales eight-fold, developed a new genetic-based testing platform and partnered with a large insurance provider to initiate studies leading to reimbursement of the Company’s lead product. Prior to joining Interleukin Genetics, Mr. Bender held numerous positions at Emisphere Technologies, Inc., a drug delivery company specializing in the oral delivery of poorly absorbed molecules. While at Emisphere from 1993 to December of 2007 Mr. Bender held positions as; Interim President & CEO, Chief Technology Officer, Senior Vice President of Business Development, and Vice President of Manufacturing and Process Development. During his career Mr. Bender has partnered with several major pharmaceutical and biotech companies using structures such as joint ventures, licensing and research collaboration agreements. Mr. Bender has over 25 years of biotech and pharmaceutical experience having led teams taking products from discovery to Phase III for compounds using novel drug delivery techniques. In addition, Mr. Bender has been successful in raising (or helping to raise) capital with institutional investors using several vehicles such as registered direct placements, PIPES, S-3 & S-1 filings, and convertible debt. For Intensity Therapeutics he has raised approximately $13,000,000 in capital with multiple types of investors.
Mr. Bender has both a S.B. and S.M. in Chemical Engineering from MIT, an MBA from UPENN’s Wharton School, and an MA in International studies also from UPENN. He spent several years living in Switzerland and speaks French, German and Swiss-German dialect.